PVCT Provectus Biopharmaceuticals, Inc.
Listings ·
Provectus holders authorized a reverse split of between 1-for-10 and 1-for-50, with the ratio left to the board, and a matching cut in authorized shares. The company had $251,291 of cash at December 31, 2025, and its net loss widened to $5.4 million.
The unsecured notes carry 8% interest and convert into Series D-1 preferred stock at $2.8620 per share. The board also approved the closing of a 2024 financing under which the company had received $1,000,000 in notes.
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines based on pharmaceutical-grade rose bengal sodium (RBS), a halogenated xanthene small molecule. The company says it is the first to advance RBS into clinical trials for the treatment of disease. Its candidates use different amounts of RBS, delivered by different routes, for each disease area. Clinical programs include intratumoral PV-10 in oncology, with pre-operative penile squamous cell carcinoma and FOLRINOX-refractory pancreatic ductal adenocarcinoma metastatic to the liver as co-lead indications. Topical PH-10 in dermatology has undergone multiple mid-stage trials for psoriasis and atopic dermatitis. Topical PV-305 for eye disorders such as infectious keratitis has undergone non-clinical study at the University of Miami's Bascom Palmer Eye Institute. Proof-of-concept and discovery programs cover oncology, hematology, wound healing, vaccine adjuvants, infectious diseases and computer modeling of amyotrophic lateral sclerosis.
| Product or program | What it is | Stage |
|---|---|---|
| PV-10 | Intratumoral rose bengal formulation for melanoma and liver cancers | early-stage clinical trials for co-lead indications |
| PH-10 | Topical PV-10 formulation for psoriasis and atopic dermatitis | multiple mid-stage clinical trials |
| PV-305 | Topical PV-10 formulation for eye disorders such as infectious keratitis | non-clinical combination study |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.9 million | $2.1 million |
| Net income (loss) | -$5.4 million | -$4.7 million |
| Cash from operations | -$3.3 million | -$3.3 million |
| Cash and equivalents | $251,291 | $307,442 |
Our latest story on this, dated Jun 22, 2026: "Provectus holders authorize reverse split of between 1-for-10 and 1-for-50". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 22, 2025: "Provectus Biopharmaceuticals approves plan to seek up to $10,000,000 in convertible notes". The story links the filing or release it is based on. Read the story.
Provectus Biopharmaceuticals, Inc. trades under the ticker PVCT on OTC.
Provectus Biopharmaceuticals, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Provectus Biopharmaceuticals, Inc. is 315545. Its filings are on SEC EDGAR.
420,279,879 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Provectus Biopharmaceuticals, Inc. under United States.
Our directory classifies Provectus Biopharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Provectus Biopharmaceuticals, Inc. is US74373P1084.
aibio.space lists Provectus Biopharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines based on pharmaceutical-grade rose bengal sodium (RBS), a halogenated xanthene small molecule. The company says it is the first to advance RBS into clinical trials for the treatment of disease.
PV-10: Intratumoral rose bengal formulation for melanoma and liver cancers Stage: early-stage clinical trials for co-lead indications.
PH-10: Topical PV-10 formulation for psoriasis and atopic dermatitis Stage: multiple mid-stage clinical trials.
Provectus Biopharmaceuticals, Inc. reported a net loss of $5.4 million for the fiscal year ended Dec 31, 2025, and used $3.3 million of cash in operations, per its annual report to the SEC.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio